J&J's $230M blood pressure bet hits phase 3 endpoint, but questions linger about blockbuster potential

Johnson & Johnson’s $230 million blood pressure bet has hit the mark in phase 3. The Idorsia-partnered prospect significantly reduced blood pressure in patients with resistant hypertension, although the rate of fluid retention and initial lack of detail on efficacy leave scope to question whether it will live up to its blockbuster billing.